Securities code: Guizhou Yibai Pharmaceutical Co.Ltd(600594) securities abbreviation: Guizhou Yibai Pharmaceutical Co.Ltd(600594) Announcement No.: 2022001 Guizhou Yibai Pharmaceutical Co.Ltd(600594) about subsidiaries
Announcement on participating in the centralized procurement of diclofenac and other drugs by Guangdong Alliance
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Recently, Hainan Chang'an International Pharmaceutical Co., Ltd. (hereinafter referred to as "Chang'an pharmaceutical"), a subsidiary of Guizhou Yibai Pharmaceutical Co.Ltd(600594) (hereinafter referred to as "the company"), participated in the bidding for centralized procurement of diclofenac and other drugs by Guangdong alliance. According to the publicity form of the proposed winning / alternative results of the centralized procurement of diclofenac and other drugs of Guangdong Alliance (the first batch) issued by Guangdong provincial drug trading center on March 10, 2022, the company's subsidiary Chang'an pharmaceutical products for injection lobaplatin is proposed to be selected for this centralized procurement. The relevant information is hereby announced as follows:
1、 Basic information of products to be selected
The proposed winning price of publicity materials is proposed to be supplied to the province, the specification of procurement indications is proposed to be selected, and the quantity is proposed to be selected
Species name lattice (area) cycle
Mainly used in the first year: the enterprise in the alliance area, Guangdong and Shandong
Pre procurement volume in the first year of treatment procurement period: West, Jiangxi
Breast 100% (349960 branches) and Henan and Guangzhou
10mg
Cancer, small gain incremental use, West, Hainan
For injection (no 3591928)
The second year of cell lung: re report the volume, and the original Guizhou and Qinghai lobaplatin water matter elements in the past two years
In terms of cancer and slow growth, it shall not be less than the first year's agreement on sea mining, Ningxia
(total)
Purchase quantity of fine grain (specific quantity to be determined by each sheet)
Production and construction soldiers in cellular baimeng area after distribution
Blood disease identification group
The proposed successful selection and the number of the above varieties are subject to the final data released by Guangdong pharmaceutical trading center.
2、 The impact of this election on the company
The specifications of lobaplatin for injection of the company's subsidiary Chang'an pharmaceutical are divided into 10mg (based on anhydrous matter) and 50mg (based on anhydrous matter). The selected product is lobaplatin for injection (10mg), and lobaplatin for injection (50mg) has not participated in the bidding this time. In 2020, the total sales revenue of lobaplatin for injection was 9715185 million yuan, accounting for 28.46% of the company's total operating revenue in 2020; The total sales revenue from January to September 2021 was 706.76 million yuan, accounting for 27.12% of the company's total operating revenue from January to September 2021.
The sales revenue of lobaplatin for injection (10mg) in 2020 was 6612385 million yuan, accounting for 19.37% of the company's total operating revenue in 2020; The sales revenue from January to September 2021 was 466751500 yuan, accounting for 17.91% of the company's total operating revenue from January to September 2021.
The sales revenue of lobaplatin for injection (50mg) in 2020 was 310.28 million yuan, accounting for 9.09% of the company's total operating revenue in 2020; The sales revenue from January to September 2021 was RMB 240085 million, accounting for 9.21% of the company's total operating revenue from January to September 2021.
If the products to be selected are confirmed to be selected, the medical institutions in the alliance area will give priority to the selected products in the centralized drug procurement, and ensure the completion of the agreed procurement volume. The proposed winning price of lotplatin for injection of Changan pharmaceutical products, a subsidiary of the company, decreased by 18% compared with the original benchmark price. If the company signs and implements the subsequent purchase and sales agreement, it will help to further expand the sales scope of the winning products, improve the market share of the winning products, enhance the brand influence of the company, and have a positive impact on the long-term development of the company.
3、 Risk tips
(I) the publicity period for the selection of the above products is from March 10, 2022 to March 14, 2022, and the selection results are still uncertain.
(II) the purchase contract related to the above products has not been signed, and the subsequent matters and the impact on the company are still uncertain.
The company will pay close attention to the progress of the matter and fulfill the obligation of information disclosure in time. Please make careful decisions and pay attention to investment risks.
It is hereby announced.
Guizhou Yibai Pharmaceutical Co.Ltd(600594) board of directors March 14, 2022
